FDA approves Protalix/Pfizer Gaucher drug
Elelyso, derived from ProCellEx, is an enzyme replacement therapy (ERT) for the long-term treatment of adults with type 1 Gaucher disease. The plant cell-expressed drug is a form
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.